The Danish Cosmos Anemia Management Satellite will be successfully held - iron isomaltose iron breaks through the limitations of iron supplementation, and it is safe at one time

Listening to the sound of blood and perceiving the rhythm of life, the "17th National Hematology Academic Conference of the Chinese Medical Association" hosted by the Chinese Medical Association and the Hematology Branch of the Chinese Medical Association, hosted by the Shanghai Medical Association, co-organized by Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the First Affiliated Hospital of Soochow University, and the Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, was

Anemia is one of the most common types of diseases in the field of blood, among which iron deficiency anemia (IDA) brings a heavy disease burden to patients in China, and it is urgent to explore more efficient treatment options clinically

Based on the current situation, the clinical needs of patients with iron deficiency anemia still need to be met

The 2021 WHO report shows that the number of anemia patients worldwide is as high as 2.

Figure 1 Professor Fu Rong shares the current situation and hazards of iron deficiency anemia

At present, although many clinical disciplines have strengthened their attention to IDA, and have successively formulated relevant consensus or guidelines such as recommendations for the prevention and treatment of iron deficiency and iron deficiency anemia in children, guidelines for iron deficiency and iron deficiency anemia in pregnancy, and clinical practice guidelines for tumor-associated anemia, the treatment degree of patients with anemia is still seriously insufficient, the treatment rate is low, the compliance is poor, and the clinical needs need to be met

Analyzing the argument, IDA treatment urgently needs preparation innovation to break through the limitations of iron supplementation

IDA may be associated

Figure 2 Prof.

At present, the basic principle of IDA treatment is to eliminate the cause, adequate iron supplementation, usually 50 ~ 70kg of adults need to supplement 1000mg or more of elemental iron, to ensure that the body can synthesize hemoglobin, so that the body's iron storage reaches a normal level

Innovation-led, ferric isomaltose brings efficient and safe selection for IDA treatment The domestic and foreign guidelines have recommended
the application of intravenous iron.

International consensus on perioperative anaemia and iron deficiency (2017) recommends that iron-deficient patients with intravenous iron who are ineffective or intolerant of oral iron and who plan surgery within 6 weeks are the first-line option
.

The Chinese expert consensus on the application of intravenous iron in China (2019) points out that patients who do not need frequent visits can choose to infuse iron 1-2 times, such as iron
isomaltohydride.

Figure 3 Prof.
Fu Rong shares the advantages of iron isomaltose anhydride treatment

Iron isomaltose is the latest generation of intravenous iron, using an innovative matrix nanostructure, better stability, less unstable iron, to solve the problem of the second generation of intravenous iron due to unstable iron toxicity and can not be administered in a single full dose, thus bringing an innovative treatment plan can achieve an intravenous infusion of ≥ 1000mg (not more than 20mg / kg body weight), infusion of 15-30 minutes to complete the treatment
.

Studies have shown that 1 time isomaltose iron 1000mg than 5 times sucrose iron 200mg faster improvement of hemoglobin, and the risk of severe infusion reaction is lower, breaking through the treatment limitations of second-generation iron, for patients who are difficult to seek frequent medical treatment, limited hospital days can not be enough iron supplementation, or need to quickly achieve surgical indications, iron isomaltic anhydride provides a more certain, convenient, safe and efficient solution
.

Summary of the meeting

Figure 4 Professor Zhang Xi made a wonderful summary

Professor Zhang Xi, the chairman of the conference, summed up Professor Rong's wonderful sharing, saying that IDA is a common disease in the world, especially in developing countries, but everyone's understanding of the disease is seriously insufficient, and in the past IDA treatment, due to the limitation of low doses and high frequencies of intravenous iron treatment, iron deficiency
cannot be corrected at one time.

The emergence of iron isomaltose anhydride has brought a more efficient, convenient and safe new treatment plan
for IDA patients.

It is expected that more clinical exploration will be carried out in the future, and evidence-based medical evidence will be accumulated, and the clinical standardization of intravenous iron agents will be further promoted
.

Editor: Valamor Review: Janet Typography : Moly Execution: Moly

Poke "Read the original article" to see more